Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a biopharmaceutical and rare disease company with approved and investigational therapies targeting rare liver and neurodevelopmental conditions. The Mirum news feed on Stock Titan aggregates company announcements, press releases and corporate disclosures so readers can follow how its commercial portfolio and pipeline evolve over time.
Investors and followers of MIRM can review news about LIVMARLI (maralixibat), CHOLBAM (cholic acid) and CTEXLI (chenodiol), including regulatory updates, commercial milestones and clinical study developments. Coverage also includes updates on clinical-stage programs such as volixibat for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug for chronic hepatitis delta virus (HDV) in connection with the proposed Bluejay Therapeutics acquisition, and MRM-3379 for Fragile X syndrome (FXS).
News items commonly highlight Mirum’s participation in healthcare and investor conferences, private placement financings, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and material events reported via Form 8-K filings. Company press releases also discuss regulatory designations, study initiations, enrollment updates and planned timelines for key clinical readouts, as described in Mirum’s own communications.
This page offers a centralized view of Mirum-related headlines, allowing readers to track commercial performance commentary, pipeline progress and transaction announcements in one place. For users researching MIRM stock or the company’s rare disease programs, the news feed provides direct access to the narrative Mirum shares with the market.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced Health Canada authorization of the LIVMARLI tablet formulation for treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) who weigh 22 kg or more and can swallow tablets.
The tablet complements the existing 9.5 mg/mL oral solution previously authorized for patients aged 12 months and older, offering an additional dosing option to support adherence and continuity of care. Mirum also announced Health Canada authorization for LIVMARLI in progressive familial intrahepatic cholestasis (PFIC) earlier the same day, covering both 19 mg/mL solution and tablet formulations.
Mirum Pharmaceuticals (NASDAQ: MIRM) announced Health Canada authorization of LIVMARLI (maralixibat) for treatment of cholestatic pruritus in patients aged 12 months and older with progressive familial intrahepatic cholestasis (PFIC).
Authorization covers a 19 mg/mL oral solution and a tablet formulation (for patients ≥22 kg) and is supported by Phase 3 MARCH data (93 patients; p<0.0001 versus placebo).
Mirum Pharmaceuticals (NASDAQ: MIRM) completed its acquisition of Bluejay Therapeutics, acquiring worldwide rights to brelovitug, a late‑stage monoclonal antibody for chronic hepatitis delta virus (HDV).
Brelovitug holds FDA Breakthrough Therapy and EMA PRIME designations and is in the global AZURE Phase 3 registrational program with topline data expected in 2H 2026. Mirum financed the deal via cash and stock consideration plus potential tiered sales‑based milestones and closed concurrent private placement financings raising approximately $268.5 million to support clinical development and commercial activities.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement grants made on January 9, 2026 to five new employees under its 2020 Inducement Plan. The Compensation Committee granted non-qualified stock options to purchase 4,900 shares and 6,500 restricted stock units (RSUs).
Each option has an exercise price of $86.57 per share (Mirum's closing price on January 9, 2026). Options vest over four years (25% at one year, then monthly over 36 months). RSUs vest over three years (33% on each anniversary). Grants are subject to the 2020 Inducement Plan and applicable award agreements and to continued service through vesting dates.
Mirum Pharmaceuticals (NASDAQ: MIRM) reported preliminary unaudited full-year 2025 results and 2026 outlook. 2025 net product sales were approximately $520 million, above the top of guidance. Management expects 2026 net product sales of $630M–$650M. 2025 LIVMARLI net sales were ~$359M (including ~$243M US), +69% YoY; CHOLBAM and CTEXLI combined ~$161M, +31% YoY. Year-end cash, cash equivalents and investments are expected to be ~$392M vs $292.8M a year earlier. Key upcoming catalysts: volixibat VISTAS PSC topline Q2 2026, LIVMARLI EXPAND topline Q4 2026, and proposed Bluejay acquisition with AZURE HDV data in H2 2026 (pending close).
Enthorin Therapeutics announced that licensing partner Mirum Pharmaceuticals (NASDAQ: MIRM) initiated the BLOOM Phase 2 clinical study of MRM-3379 (formerly ENT-3379) in Fragile X syndrome in December. MRM-3379 is described as an orally available, highly brain-penetrant, selective PDE4D inhibitor designed to enhance cAMP signaling. The compound was discovered at Dart Neuroscience and advanced through Phase 1; preclinical data in an FMR1 knockout mouse reportedly showed improved cognition and reduced behavioral deficits. Enthorin acknowledged the clinical and scientific teams involved in the decade-long research and development leading to this patient-trial milestone.
Mirum Pharmaceuticals (NASDAQ: MIRM) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 11:15 a.m. PT. The company said the presentation and subsequent Q&A will be webcast live and accessible via the Investors section of Mirum’s corporate website.
This provides investors and analysts live access to Mirum’s corporate presentation and management Q&A during the conference.
Mirum Pharmaceuticals (Nasdaq: MIRM) entered a subscription agreement with entities associated with TCGX for a private placement of 1,000,000 common shares at $68.48 per share, raising approximately $68.5 million in gross proceeds.
Combined with a previously announced $200 million private placement, the proceeds are intended to fund clinical development and commercial activities related to the proposed acquisition of Bluejay Therapeutics. Both private placements are expected to close concurrently with the proposed Bluejay acquisition in Q1 2026, subject to regulatory approval and customary closing conditions. The shares are being sold in a private transaction and are not registered under the Securities Act; Mirum and the investors executed registration rights that will become effective at closing.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement equity awards granted on December 10, 2025 to eight new employees under its 2020 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The Compensation Committee granted non‑qualified stock options to purchase 15,820 shares and 7,840 restricted stock units (RSUs). Each option has an exercise price of $64.67, equal to Mirum’s closing price on December 10, 2025. Options vest over four years (25% at one year, then monthly over 36 months); RSUs vest over three years (33% each anniversary), both subject to continued service and the applicable award agreements.
Mirum Pharmaceuticals (Nasdaq: MIRM) entered a definitive agreement to acquire Bluejay Therapeutics, gaining worldwide rights to brelovitug, a late‑stage monoclonal antibody for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations.
The deal consideration is $250M cash + $370M in Mirum stock (priced at $71.2085/share) plus up to $200M in sales‑based cash milestones. Mirum also arranged a private placement to raise ~$200M concurrent with closing. AZURE Phase 3 top‑line data expected 2H 2026 with potential BLA submission and launch in 2027. Closing expected Q1 2026, subject to approvals and customary conditions.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
